|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 746.80 USD | +2.84% |
|
+3.32% | +4.84% |
| 11:10am | US FDA brass pushed internally for speedier Lilly weight-loss pill verdict | RE |
| 12-10 | Regeneron Pharmaceuticals, Inc. - Special Call |
| Capitalization | 76.62B 65.19B 60.86B 57.1B 106B 6,911B 115B 709B 276B 3,265B 288B 281B 11,896B | P/E ratio 2025 * |
18.3x | P/E ratio 2026 * | 19.5x |
|---|---|---|---|---|---|
| Enterprise value | 70.05B 59.6B 55.64B 52.2B 96.53B 6,319B 105B 648B 252B 2,985B 263B 257B 10,876B | EV / Sales 2025 * |
4.93x | EV / Sales 2026 * | 4.5x |
| Free-Float |
77.36% | Yield 2025 * |
0.49% | Yield 2026 * | 0.52% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | -1.49% | ||
| 1 week | +3.32% | ||
| Current month | -4.28% | ||
| 1 month | +10.71% | ||
| 3 months | +31.43% | ||
| 6 months | +44.00% | ||
| Current year | +4.84% |
| 1 week | 691.86 |  | 753.61 |
| 1 month | 679.93 | | 790.98 |
| Current year | 476.49 | | 790.98 |
| 1 year | 476.49 | | 790.98 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 441 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 65 | 31/12/2000 | |
| Chief Executive Officer | 72 | 07/01/1988 | |
| Director of Finance/CFO | 54 | 04/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 72 | 08/06/2023 | |
Michael Brown
BRD | Director/Board Member | 84 | 31/05/1991 |
Joseph Goldstein
BRD | Director/Board Member | 84 | 31/05/1991 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.84% | +3.32% | -3.39% | -0.43% | 76.62B | |
| +2.86% | -0.09% | -33.92% | -38.32% | 57.54B | |
| -2.20% | -4.69% | +29.83% | +226.82% | 53.75B | |
| +0.24% | +66.90% | +66.90% | +66.90% | 52.52B | |
| -2.84% | -5.21% | +9.55% | -39.55% | 25.31B | |
| +0.98% | -4.34% | +32.57% | +16.71% | 18.87B | |
| +1.85% | -7.39% | +123.62% | +166.25% | 18.42B | |
| -0.66% | -12.62% | +47.24% | +1,004.75% | 16.49B | |
| -0.04% | -.--% | +57.21% | +154.72% | 14.02B | |
| +1.88% | -0.93% | +155.57% | +733.13% | 14.27B | |
| Average | +0.08% | -2.00% | +48.52% | +229.10% | 34.78B | |
| Weighted average by Cap. | -0.14% | -0.81% | +28.29% | +129.51% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 14.2B 12.09B 11.28B 10.59B 19.57B 1,281B 21.31B 131B 51.08B 605B 53.3B 52.17B 2,205B | 15.11B 12.85B 12B 11.26B 20.82B 1,363B 22.66B 140B 54.32B 644B 56.69B 55.49B 2,345B |
| Net income | 4.14B 3.52B 3.29B 3.08B 5.7B 373B 6.21B 38.3B 14.88B 176B 15.53B 15.2B 643B | 4.03B 3.43B 3.2B 3B 5.55B 364B 6.05B 37.31B 14.5B 172B 15.13B 14.81B 626B |
| Net Debt | -6.57B -5.59B -5.22B -4.9B -9.05B -593B -9.86B -60.81B -23.63B -280B -24.66B -24.13B -1,020B | -8.63B -7.35B -6.86B -6.43B -11.9B -779B -12.95B -79.9B -31.05B -368B -32.4B -31.71B -1,341B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/12/25 | 746.80 $ | +2.84% | 1,153,882 |
| 10/12/25 | 726.21 $ | +4.86% | 1,316,662 |
| 09/12/25 | 692.58 $ | -1.52% | 604,535 |
| 08/12/25 | 703.26 $ | -2.10% | 1,005,953 |
| 05/12/25 | 718.36 $ | -0.61% | 798,452 |
Delayed Quote Nasdaq, December 11, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition